Tuberculosis treatment-related lichenoid drug eruptions
International Journal of Mycobacteriology, cilt.11, sa.4, ss.469-471, 2022 (ESCI, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 11 Sayı: 4
- Basım Tarihi: 2022
- Doi Numarası: 10.4103/ijmy.ijmy_151_22
- Dergi Adı: International Journal of Mycobacteriology
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
- Sayfa Sayıları: ss.469-471
- Anahtar Kelimeler: Drug hypersensitivity, lichenoid drug eruptions, tuberculosis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Tuberculosis is one of the leading causes of death from infectious diseases in adults worldwide. Drug hypersensitivity in tuberculosis is an important problem affecting the treatment process. Although treatment is started with isoniazid, rifampicin, ethambutol, and pyrazinamide in drug-sensitive tuberculosis patients, it may not always be continued in this way. When hypersensitivity develops under antituberculosis treatment, type 4 hypersensitivity is the most common, and maculopapular drug eruption develops as a subgroup. Lichenoid drug eruption is very rare. We present our case who was diagnosed with pulmonary tuberculosis, who developed lichenoid drug eruption while receiving treatment, and whose treatment was completed by giving the new regimen with successful desensitization.